Mutual interaction between daikenchuto and calcitonin gene–related peptide

Abstract

I reviewed the mutual interaction between daikenchuto and calcitonin gene–related peptide (CGRP) based on the studies in the available literature. Daikenchuto does not aggravate migraine headaches. Moreover, it does not affect the therapeutic effects of anti–CGRP monoclonal antibodies. In contrast, anti–CGRP monoclonal antibodies may affect the therapeutic effects of daikenchuto. However, owing to the intermittent effects of daikenchuto, continuous blockage of CGRP may not be a major clinical problem. Daikenchuto is effective for improving constipation in patients treated with anti–CGRP monoclonal antibodies. I confirmed this effect in some patients.